Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.

News Releases

view all
    • News in Focus
        • Browse News Releases

        • All Public Company News
        • All Multimedia News
        • View All News Releases

        • Regulatory News

        • D/A/CH Regulatory News
        • UK Regulatory News
        • View All Regulatory News

    • Business & Money
        • Auto & Transportation

        • Aerospace & Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads & Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking & Road Transportation
        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers & Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalisation
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls & Research
        • Trade Show News
        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil & Gas Discoveries
        • Utilities
        • Water Utilities
        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defence
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation & Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking & Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers & Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines & Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics & Personal Care
        • Fashion
        • Food & Beverages
        • Furniture & Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewellery
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • View All Sports

        • Travel

        • Amusement Parks & Tourist Attractions
        • Gambling & Casinos
        • Hotels & Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Animal Welfare
        • Corporate Social Responsibility
        • Economic News, Trends & Analysis
        • Education
        • Environmental
        • European Government
        • Labour & Union
        • Natural Disasters
        • Not For Profit
        • Public Safety
        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Enquiries
    • Media Enquiries
    • Partnerships
    • Hamburger menu
    • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
    • Send a Release
      • Phone

      • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

      • ALL CONTACT INFO
      • Contact Us

        +44 (0)20 7454 5110
        from 8 AM - 5:30 PM GMT

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • 2 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • General Enquiries
      • Media Enquiries
      • Partnerships
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Regulatory News
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      TOP-REAL investigates whether digital monitoring can support earlier detection of toxicities and preserve continuity of one of the most effective treatments for HER2-positive metastatic breast cancer

      This image opens in the lightbox

      News provided by

      Solti

      20 Nov, 2026, 12:21 GMT

      Share this article

      Share this article


      • The international academic study, led from Spain by Solti, in collaboration with Unicancer in France and WSG in Germany, has presented at ESMO AI & Digital Oncology 2026 a design that integrates digital tools to monitor symptoms and physiological changes between hospital visits
      • TOP-REAL proposes a proactive monitoring model to assess whether earlier anticipation of toxicities can prevent them from compromising continuity of first-line treatment with trastuzumab deruxtecan (T-DXd) plus pertuzumab
      • Monitoring includes electronic patient-reported outcomes (ePROs), pulse oximetry and continuous physiological data collection via smartwatches, with alerts that can support earlier clinical assessment
      • The study plans to include approximately 300 patients across 60 centres in Spain, France and Germany and seeks to generate evidence in a broader population that is closer to routine clinical practice, including profiles that are underrepresented in pivotal trials, such as selected patients with active brain metastases or ECOG performance status 2

      BARCELONA, Spain, Nov. 20, 2026 /PRNewswire/ -- Solti, an academic cancer clinical research group, has presented at the European ESMO AI & Digital Oncology 2026 congress the design of TOP-REAL, an international academic phase II study evaluating a proactive monitoring model for patients with advanced or metastatic HER2-positive breast cancer receiving first-line trastuzumab deruxtecan (T-DXd) plus pertuzumab.

      Continue Reading
      This image opens in the lightbox
      TOP-REAL investigates whether digital monitoring can support earlier detection of toxicities

      The study incorporates digital tools to extend patient monitoring beyond hospital visits and assess whether identifying symptoms and physiological changes can support earlier evaluation and more timely management of toxicities before they worsen and compromise treatment continuity.

      "We want patients not only to benefit from advances that allow better control of their disease, but also to live better during treatment. Ultimately, TOP-REAL was conceived with a dual ambition: to improve clinical outcomes and place patients' quality of life at the center of care," explained Dr. Cristina Saura, principal investigator of TOP-REAL, member of the Solti Board, Head of the Breast Cancer Unit at Vall d'Hebron University Hospital and Head of the Breast Cancer Group at VHIO.

      Led by Solti from Spain, TOP-REAL plans to include approximately 300 patients and is already active in all three participating countries: Spain, France and Germany, with patients already on study in the first two and recruitment open in Germany. The study is conducted in collaboration with the academic groups Unicancer and WSG in France and Germany, respectively.

      Making what happens between visits visible

      The increasing effectiveness of treatments for HER2-positive breast cancer has made toxicity management an increasingly important part of therapeutic benefit. Adverse events can affect quality of life and, in certain circumstances, require dose modifications, treatment interruptions or discontinuation.

      "Precisely because treatments are becoming increasingly effective and allow patients to live longer, we need to pay growing attention to how they live during that time," added Dr. Saura.

      Among the toxicities that TOP-REAL will specifically assess is interstitial lung disease or pneumonitis associated with T-DXd. The study includes daily oxygen saturation measurements using pulse oximetry and periodic exercise tests to explore whether certain changes may support earlier medical assessment. This approach is exploratory.

      A population closer to routine clinical practice

      TOP-REAL will include profiles that are underrepresented in pivotal trials, such as selected patients with active brain metastases or ECOG performance status 2, with the aim of generating evidence in a population closer to routine clinical practice.

      Dr. Santiago Escrivà, principal investigator of TOP-REAL, Medical Oncologist at Vall d'Hebron University Hospital and Researcher in the Breast Cancer Group at VHIO, has discussed what additional knowledge the study may generate compared with trials that have already demonstrated the efficacy of T-DXd plus pertuzumab: "The TOP-REAL trial is contributing to the implementation of trastuzumab deruxtecan and pertuzumab in a real-world setting, a treatment with unprecedented efficacy. It allows us to better understand how we can make this treatment available to a broader range of patient profiles and optimize the management of potential toxicities by leveraging digital tools to maintain and improve quality of life."

      TOP-REAL will assess treatment benefit and continuity through time to first subsequent anticancer therapy and will evaluate health-related quality of life, including changes in physical functioning through the EORTC QLQ-C30, a questionnaire used in oncology to assess different dimensions of patients' quality of life.

      A European collaboration to study how to translate innovation into clinical practice

      Prof. Nadia Harbeck, principal investigator of TOP-REAL and Director of the Breast Center of the Department of Obstetrics and Gynecology and the Comprehensive Cancer Center Munich at LMU University Hospital in Munich (Germany), has highlighted the international dimension of the project.

      In addition to toxicity management and quality of life, TOP-REAL will explore the feasibility and safety of T-DXd rechallenge in selected patients and will include analyses of tumour biopsies and blood samples to study biomarkers related to treatment response and toxicity.

      Digital and patient-centred follow-up

      TOP-REAL combines a mobile application -CANKADO or Resilience, depending on the country and centre-, electronically reported patient outcomes (ePROs), pulse oximetry and smartwatch monitoring. These tools allow patients to report symptoms and physiological changes between hospital visits and can generate recommendations or alerts, depending on the platform.

      "Identifying a toxicity early can make a major difference to a patient's experience during treatment. We want to move from a model in which we wait for the patient to tell us about a problem when she comes to the clinic to one in which we can anticipate issues, support her more closely and help her manage side effects better," added Dr. Saura.

      Dr. Inês Vaz-Luis, principal investigator of TOP-REAL and medical oncologist and researcher at Gustave Roussy (Paris, France), has explained the value and novelty of the TOP REAL approach: "TOP-REAL offers a unique opportunity to integrate innovative, patient-centred supportive care pathways into a clinical trial providing patients with access to a new and effective treatment, with the potential to further improve their care experience and outcomes. By adopting a pragmatic, flexible approach that leverages existing digital platforms and adapts to different healthcare systems, TOP-REAL will demonstrate how these pathways can be integrated into routine care across diverse settings, ensuring harmonised, high-quality supportive care for patients regardless of their healthcare setting."

      Sponsored by Solti, TOP-REAL is conducted in collaboration with Unicancer and West German Study Group (WSG) and is supported by AstraZeneca and Daiichi Sankyo.

      Irene Alcón
      irene.alcon@gruposolti.org
      External Communications Officer

      Modal title

      Contact PR Newswire

      • +44 (0)20 7454 5110
        from 8 AM - 5:30 PM GMT
      • General Enquiries
      • Media Enquiries
      • Partnerships

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United States
      • Vietnam

      My Services

      • All News Releases
      • PR Newswire Amplify™
      • Resources
      • Journalists
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via Privacy@cision.com 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Customer Portal
      • Resources
      • Journalists
      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookie Settings
      Copyright © 2026 PR Newswire Europe Limited. All Rights Reserved. A Cision company.